AstraZeneca PLC (AZN.L)
| Previous close | 8,559.00 |
| Open | 8,560.00 |
| Bid | 8,681.00 x 0 |
| Ask | 8,684.00 x 0 |
| Day's range | 8,507.00 - 8,710.00 |
| 52-week range | 6,499.80 - 8,848.00 |
| Volume | 3,288,640 |
| Avg. volume | 3,353,701 |
| Market cap | 134.929B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 41.65 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.02 (2.36%) |
| Ex-dividend date | 12 Aug 2021 |
| 1y target est | N/A |
- Business Wire
IMFINZI plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial in extensive-stage small cell lung cancer
WILMINGTON, Del., September 18, 2021--Updated results from the CASPIAN Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin, demonstrated a sustained, clinically meaningful overall survival (OS) benefit at three years for adults with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
WILMINGTON, Del., September 18, 2021--Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superior progression-free survival (PFS) versus trastuzumab emtansine (T-DM1), a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic b
- Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated robust and durable tumor response of 54.9% in patients with HER2-mutant metastatic non-small cell lung cancer
WILMINGTON, Del., September 18, 2021--Detailed primary results from the positive Phase II DESTINY-Lung01 trial of ENHERTU® (fam-trastuzumab deruxtecan-nxki), the AstraZeneca and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), showed a robust and durable tumor response in previously treated patients with HER2-mutant (HER2m) unresectable and/or metastatic non-squamous non-small cell lung cancer (NSCLC). Results presented during a late-breaki
